Compare Adobe Systems Inc (ADBE) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Adobe Systems Inc trades at $220.75 (market cap $88.06B), while Ginkgo Bioworks Holdings Inc trades at $8.89 (market cap $610.13M). The key difference: Adobe Systems Inc is far larger — about 144.3× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | DNA | |
|---|---|---|
Market Cap | $88.06B | $610.13M |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $16.14 |
52-Week Low | $193.41 | $5.48 |
Enterprise Value | $89.50B | $647.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $220.35, up 1.05% with a bullish technical signal. The company reported strong Q1 2026 earnings of $5.96 EPS, beating estimates, and maintains robust profitability with 89.4% gross margins. Revenue growth accelerated to $23.77B in 2025, while valuation ratios remain attractive with P/E at 12.67. Recent institutional buying activity contrasts with some analyst concerns about AI competition.
Adobe presents a compelling investment case with strong fundamentals and growth trajectory, though AI disruption risks and recent stock volatility warrant caution. The consensus price target of $246.75 suggests 12% upside potential, supported by consistent earnings beats and expanding cash flows.
DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.
The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
